Kondo Naoya, Hirano Fuko, Temma Takashi
Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan.
Pharmaceutics. 2022 May 22;14(5):1106. doi: 10.3390/pharmaceutics14051106.
Although 4-borono-l-phenylalanine (4-BPA) is currently the only marketed agent available for boron neutron capture therapy (BNCT), its low water solubility raises concerns. In this study, we synthesized 3-borono-l-phenylalanine (3-BPA), a positional isomer of 4-BPA, with improved water solubility. We further evaluated its physicochemical properties, tumor accumulation, and biodistribution. The water solubility of 3-BPA was 125 g/L, which is more than 100 times higher than that of 4-BPA. Due to the high water solubility, we prepared the administration solution of 3-BPA without a solubilizer sugar, which is inevitably added to 4-BPA preparation and has adverse effects. In in vitro and in vivo experiments, boron accumulation in cancers after administration was statistically equivalent in both sugar-complexed 3-BPA and 4-BPA. Furthermore, the biodistribution of 3-BPA was comparable with that of sugar-complexed 3-BPA. Since 3-BPA has high water solubility and tumor targetability equivalent to 4-BPA, 3-BPA can replace 4-BPA in future BNCT.
尽管4-硼-L-苯丙氨酸(4-BPA)是目前唯一可用于硼中子俘获疗法(BNCT)的上市药物,但其低水溶性引发了人们的担忧。在本研究中,我们合成了4-BPA的位置异构体3-硼-L-苯丙氨酸(3-BPA),其水溶性得到了改善。我们进一步评估了其理化性质、肿瘤蓄积和生物分布。3-BPA的水溶性为125 g/L,比4-BPA高100多倍。由于水溶性高,我们制备3-BPA给药溶液时无需添加增溶剂糖,而4-BPA制剂中不可避免地会添加增溶剂糖,且会产生不良影响。在体外和体内实验中,给药后癌症组织中的硼蓄积在含糖络合的3-BPA和4-BPA中在统计学上相当。此外,3-BPA的生物分布与含糖络合的3-BPA相当。由于3-BPA具有高水溶性且肿瘤靶向性与4-BPA相当,3-BPA在未来的BNCT中可以替代4-BPA。